Characterization of PI ( XXXX cell special peptide) in MDA-MB-231 @entity0 cells and its potential therapeutic applications.

@entity1 @entity137 @entity0 @entity5 @entity1014 @entity4540
Gene therapy is one of the most important aspects of molecular targeted therapeutic approaches for @entity5 . A small molecule targeting carrier plays an important role in this process. PI, a new peptide found in our phage library, has been specifically suggested, combined with the @entity1 triple-negative @entity0 cell line MDA-MB  -231, and may be developed as a targeting/individualization therapy strategy to be applied in @entity0 research. In this study, we further investigated whether this peptide could carry exogenous protein to the target cells by forming a fusion peptide. PI-GST and PI-TK were cloned into plasmids and used for expression studies, analyses of PI-mediated protein delivery efficiency, and to investigations into the effect of PI on @entity1014 kinase/ @entity4540 -mediated @entity137 . Biodistribution profiles were also investigated in vivo. The results showed the PI fusion protein was expressed correctly in vitro, and could carry GST into the target cells. Under certain conditions, PI-TK sensitizes cells to @entity4540 more efficiently than TK. In vivo there was a trend for increased inhibition of @entity5 growth with PI-TK when @entity4540 was present. Therefore, our results suggest the potential of PI as a new specific target carrier in @entity0 therapy.
